<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92428">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01901692</url>
  </required_header>
  <id_info>
    <org_study_id>AMC IRB 2013-0582</org_study_id>
    <nct_id>NCT01901692</nct_id>
  </id_info>
  <brief_title>Transarterial Chemoembolization Plus Radiotherapy or Sorafenib in Hepatocellular Carcinoma With Major Vascular Invasion</brief_title>
  <acronym>START</acronym>
  <official_title>Randomized Phase II Trial Comparing Transarterial Chemoembolization Plus External Beam Radiotherapy Versus Sorafenib in Patients With Hepatocellular Carcinoma With Major Vascular Invasion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate and compare the efficacy and safety of trans-arterial chemoembolization plus
      external beam radiation therapy and sorafenib in patients with hepatocellular carcinoma
      invading major intrahepatic vessels
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current practice guidelines recommend sorafenib for patients with hepatocellular carcinoma
      invading major intrahepatic vessels. However, recent data suggest that the combination of
      transarterial chemoembolization and external beam radiotherapy would be effective as
      sorafenib.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free rate</measure>
    <time_frame>at 3 months after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>at 3 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-failure of treatment</measure>
    <time_frame>within 6 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival of patients</measure>
    <time_frame>within 6 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>within 6 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall patient survival</measure>
    <time_frame>within 6 months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>TACE+EBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transarterial chemoembolization plus external beam radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sorafenib 800 mg/day orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TACE+EBRT</intervention_name>
    <description>Trans-arterial chemoembolization plus external beam radiation therapy</description>
    <arm_group_label>TACE+EBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib 800 mg/day orally</description>
    <arm_group_label>Sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;19 years

          -  Child-Pugh class A liver function

          -  Performance status: Eastern Cooperative Oncology Group (ECOG) score 0 or 1

          -  Hepatocellular carcinoma (HCC) confirmed by dynamic CT or MRI, or by biopsy

          -  HCC invasion of first or second branch portal vein or hepatic vein or inferior vena
             cava

          -  Reserved unilateral portal blood flow at least in partial

          -  HCC size larger than 1 cm and less than 50% of total liver volume

          -  No extrahepatic metastasis

          -  Adequate hematopoietic function Hemoglobin ≥ 8.5 g/dL Absolute neutrophil count ≥
             750/mm3 Platelet count ≥ 30,000/mm3

          -  Creatinine &lt; 1.5mg/dL

          -  No plan for pregnancy or breast feeding. Active contraception.

          -  Willing to give informed consent

        Exclusion Criteria:

          -  Prior history to or exposure of transarterial chemoembolization, external beam
             radiation to liver, or sorafenib

          -  Complete obstruction of hepatic outflow

          -  Confirmed extrahepatic metastasis of HCC

          -  HCC occupying more than 50% of liver volume

          -  Uncontrolled ascites of hepatic encephalopathy

          -  Prior liver transplantation

          -  Positive for human immunodeficiency virus (HIV)

          -  Active gastric or duodenal ulcer

          -  Other uncontrolled comorbidities or malignancy

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Suk Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 24, 2017</lastchanged_date>
  <firstreceived_date>July 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Young-Suk Lim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
